UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 ZIMVIE INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 87-2007795 | | --- | --- | | ( State or oth ...

Exhibit 99.1 ZimVie Reports First Quarter 2024 Financial Results PALM BEACH GARDENS, Florida, May 8, 2024 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time. Adjusted EBITDA[1] for the first quarter of 2024 was $12.5 million, or 10.5% of third party net sales, an increase of $1.8 million or 17 ...

Financial Data and Key Metrics Changes - Total third-party net sales for Q4 2023 were $113.1 million, a decrease of 2.4% in reported rates and a decline of 3.6% in constant currency [34] - Full year 2023 total third-party net sales were $457.2 million, essentially flat year-over-year, declining 50 basis points [34] - Adjusted EBITDA attributable to continuing operations for Q4 2023 was $13.9 million, representing a 12.3% EBITDA margin [36] - Full year 2023 adjusted EBITDA was $50.8 million, reflecting 11.1% of third-party net sales [36] - Adjusted earnings per share for continuing operations for Q4 2023 was $0.10 per share [60] Business Line Data and Key Metrics Changes - The U.S. third-party net sales for Q4 2023 were $65.4 million, a decrease of 3.2%, driven by a weaker implant market [15] - Full year 2023 U.S. sales were $327.3 million, declining 8.4% [18] - Outside the U.S., Q4 2023 third-party net sales were $18.9 million, a decrease of 11.6% on a reported basis [18] - Adjusted cost of products sold for Q4 2023 was 37.4%, compared to 34.8% in the prior year [16] Market Data and Key Metrics Changes - The dental market was soft throughout most of 2023, but the company exited the year roughly flat compared to 2022, indicating resilience [35] - The company expects Q1 sales from discontinued operations to be in the range of $89 million to $91 million [40] Company Strategy and Development Direction - The company executed an agreement to sell its Spine business to H.I.G. Capital for $375 million, addressing concerns about synergy and capital structure [5][6] - Post-sale, the company aims to become a leaner, focused pure-play Dental company with a commitment to a 15% plus adjusted EBITDA margin one year post-sale [7][26] - The company plans to invest in innovation and operational efficiency, particularly in manufacturing automation and supply chain optimization [10][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2024 as a pure-play Dental company, focusing on differentiating solutions for patients and providers [25] - The company aims to reduce net debt to under $200 million by one year post-sale [26][63] - Management acknowledged the challenges in the macroeconomic environment but remains confident in the performance of their premium implants and digital solutions [39] Other Important Information - The Spine segment is classified as discontinued operations as of the end of 2023 [14] - The company ended 2023 with a cash balance of $87.8 million and gross debt of $508.8 million, yielding a net debt balance of $421.0 million [63] Q&A Session Summary Question: How is the company addressing opportunities in the implant market? - Management noted that they have gained market share despite a slower market and emphasized the strength of their implant portfolio [69][70] Question: What is the status of the agreement with iTero regarding the new Lumina scanner? - Management confirmed that the agreement includes the new scanner, but sales will not begin until Q4 due to regulatory delays [72][74] Question: Can you quantify the stranded costs currently being incurred? - Management indicated that stranded costs are largely in SG&A within the corporate sector, with ongoing costs related to the separation of the Spine business [76] Question: How does the company plan to manage its net debt post-sale? - Management discussed the complexities of the transaction and the need to balance cash flow with debt repayment, aiming for under $200 million in net debt [92][96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41242 ZIMVIE INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organizatio ...

Exhibit 99.1 ZimVie Reports Fourth Quarter and Full Year 2023 Financial Results WESTMINSTER, Colorado, February 28, 2024 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the quarter and year ended December 31, 2023. Management will host a corresponding conference call today, February 28, 2024, at 4:30 p.m. Eastern Time. "We had significant accomplishments in 2023. We invested to further differentiate our portfo ...

WESTMINSTER, Colo., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, today announced the launch of the TSX® Implant in Japan. As ZimVie's largest dental implant market in APAC and fifth largest market globally, Japan is of great strategic importance to ZimVie. The launch of TSX in Japan allows the company to compete head-to-head with premium market leaders in the dental implant space.  TSX Implants are designed for immediate extracti ...

sorn340/iStock via Getty Images In June, I downgraded ZimVie Inc. (NASDAQ:ZIMV) to a hold, based on the company's elevated valuation and deteriorating fundamentals. For a while, my cautious stance appeared to be the right call, as ZimVie struggled to return its businesses to growth, and the stock languished, falling to $7 a share or more than 40% below my June downgrade (Figure 1). Figure 1 - ZIMV performance since last article (Seeking Alpha) However, since reporting Q3 results on November 1st, ZimVi ...

ZimVie Inc. (NASDAQ:ZIMV) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised tha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 ZIMVIE INC. Westminster, CO 80021 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification N ...

Page 2 *Assumes year-over-year Dental Net Sales growth of flat to low-single-digits, and year-over year Spine Net Sales to decline in the high single digits to low double digits, inclusive of an approximate 3.0 percentage point impact to our Spine business from our decision to exit the China market. [1] This is a forward-looking non-GAAP financial measure. See "Forward-Looking Non-GAAP Financial Measures" in the Appendix for further information. [2] Excludes one-time share-based compensation expense due to ...